Login to Your Account

Arrowhead analysts cite 'overreaction'; shares wilt on HBV trial news

By Michael Fitzhugh
Staff Writer

Thursday, October 9, 2014
Arrowhead Research Corp.'s shares (NASDAQ:ARWR) regained little ground Thursday after hitting a 52-week low at midweek as investors sold off shares over concern about the potential performance and timing of the company's experimental RNAi-based chronic hepatitis B (HBV) therapy, ARC-520.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription